Molina Healthcare (MOH) is in focus after new 2025 risk adjustment figures from the Centers for Medicare & Medicaid Services pointed to higher than expected payments for the company, alongside fresh index reclassifications and value-focused research coverage.

The recent risk adjustment update and index reshuffling come at a time when Molina Healthcare’s share price momentum has been strong, with a 30 day share price return of 26.9% and a 90 day share price return of 66.9%. This is occurring even though the 1 year total shareholder return declined 2.7% and the 3 year total shareholder return declined 22.6%, pointing to a sharp recent shift in sentiment around valuation and risk.

If you are weighing what this means for your broader healthcare exposure, it could be a good moment to see which other healthcare focused AI stocks are attracting attention via the 39 healthcare AI stocks.

With Molina Healthcare now flagged as a value stock yet trading above its average analyst price target and facing higher 2025 risk adjustment payments, investors are left with a key question: is this genuine mispricing, or has the market already priced in future growth?

Most Popular Narrative: 10.7% Undervalued

On the most followed narrative, Molina Healthcare’s fair value of $260.28 sits above the last close at $232.55, which puts the recent price surge in context for investors weighing how much upside is already implied.

The lasting demand tailwinds from an aging US population, combined with recent industry-wide underfunding and sharp acuity shifts, position Molina to capture a disproportionate share of incremental Medicaid and Medicare contracts as states increase outsourcing and funding resets occur, further accelerating top-line and earnings growth over the next several years.

Want to see what is behind that confidence in Molina Healthcare? The narrative leans on faster earnings growth, improving margins and a lower future earnings multiple than many investors might expect.

Result: Fair Value of $260.28 (UNDERVALUED)

However, Molina Healthcare’s heavy dependence on Medicaid and other government sponsored plans, combined with rising medical cost pressures, means policy shifts or stubborn cost trends could quickly challenge that bullish earnings narrative.

Another View: Multiples Paint a Different Picture for Molina Healthcare

The SWS DCF model points to Molina Healthcare trading 63.9% below its estimated future cash flow value of $645.01, yet the market is pricing the stock on a P/E of 64.4x versus a fair ratio of 44.8x, the US Healthcare industry at 24.5x and peers at 32.1x. This raises the question of whether valuation risk is building even as the model signals upside.

Next Steps

Given the mix of optimism and concern around Molina Healthcare, use this moment to review the full picture yourself and move quickly to shape your own view by weighing its 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Molina Healthcare?

If Molina Healthcare has sharpened your focus on valuation and risk, do not stop there. Use this momentum to scan other opportunities before markets move on.

• Spot potential value opportunities early by checking companies flagged as 41 high quality undervalued stocks that pair quality fundamentals with prices that may not reflect their metrics yet.
• Strengthen your income mix by reviewing 8 dividend fortresses that combine higher yields with a focus on resilience.
• Prioritize stability in tougher markets by filtering for 73 resilient stocks with low risk scores that score well on balance sheet strength and risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.